Presentation is loading. Please wait.

Presentation is loading. Please wait.

© MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after.

Published byDouglas Dorsey Modified over 8 years ago

Similar presentations

Presentation on theme: "© MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after."— Presentation transcript:

1 © MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after Sunday June 5, 11:00 AM CTZ POPLARPOPLAR 9028IINSCLC2 nd / 3 rd 144 143 24 TC3 / IC3 23 TC3 / IC3 50 TC2/3 / IC 2/3 55 TC2/3 / IC 2/3 93 TC1/2/3 / IC1/2/3 102 TC1/2/3 / IC1/2/3 51 TC0/ IC0 41 TC0/ IC0 49 Squamous 48 Squamous 95 Non-Squamous 95 Non-Squamous Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 mg IV q3w Doc q3w atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w OS12.6 9.7 NR 11.1 15.1 7.4 15.1 9.2 9.7 9.7 10.1 8.6 14.8 10.9 POPLARPOPLAR 9032IINSCLC2 nd / 3 rd 144 imRECIST 144 RECIST 57 Atezo after PD 30 Other after PD Atezo 1200 mg IV q3w Atezo 1200 mg IV q3w Atezo 1200 q3w —> PD —> Atezo dose ND Atezo 1200 q3w —> PD —> Other Tx OS17% 15% 14% 4.2 2.7 11.1 8.3 IMvigor210IImUC ≧ 2 nd 100 IC2/3 imRECIST 207 IC1/2/3 imRECIST 310 IC0/1/2/3 imRECIST 100 IC2/3 RECIST 207 IC1/2/3 RECIST 310 IC0/1/2/3 RECIST Plat CTx —> PD —> R —> Atezo 1200 q3w 29% 23% 19% 26% 18% 15% 11.9 9. 0 7.9 50 (1- Yr) 40 (1- Yr) 37 (1- Yr) Abstract 35021bCRC ≧ 1 st 23 (22 KRASmu)Cobi + Atezo 800 q2wMTD (NR)17% Abstract 10091bmTNBC1 st 2 nd ≧ 3 rd ≧ 1 st (All) 9 8 7 24 Atezo 800 q2w + Pac Safety & tolerability (NR) 67%, 89% 35%, 75% 29%, 43% 42%, 71% (Conf., TBC) Treatments: Atezo 800 = Atezolizumab 800 mg IV; Atezo 1200 = Atezolizumab 1200 mg IV; Cobi = cobimetinib 20 - 60 mg daily 3wk on, 1 wk off; Doc = docetaxel 75 mg/m 2 ; IV; Pac = Nab-paclitaxel 125 mg/m 2 on d1,8,15 of 28 day cycles;Tx = Treatment. Abbreviations: 1 o EP = Primary Endpoint; BRAFmu = BRAF mutation; C2 = Cohort 2; Conf. = Confirmed; CRC = Colorectal Cancer; IC3/2/1/0 = high/medium/low/very low PDL1 expression on tumor-infiltrating immune cells; mOS = median Overall Survival; Mo = Months; mPFS = median Progression Free Survival; mTNBC = metastatic Triple Negative Breast Cancer; mUC = metastatic urothelial cancer; NR = Not Reported; NSCLC = non-small cell lung cancer; ORR = Overall Response Rate; OS; Overall Survival; PFS: Progression Free Survival; Ph = Phase; qXwk = every X weeks; R = Registration; TBC = To be confirmed; TC3/2/1/0 = high/medium/low/very low PD-L1 expression on tumor cells; Wk = Weeks; Yr = Year.

2 © MediPaper 2016 ASCO 2016 Atezolizumab Data Courtesy of MediPaper Medical Writers - Medi-Paper.comMedi-Paper.com Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after Sunday June 5, 11:00 AM CTZ POPLARPOPLAR 9028IINSCLC2 nd / 3 rd 144 143 24 TC3 / IC3 23 TC3 / IC3 50 TC2/3 / IC 2/3 55 TC2/3 / IC 2/3 93 TC1/2/3 / IC1/2/3 102 TC1/2/3 / IC1/2/3 51 TC0/ IC0 41 TC0/ IC0 49 Squamous 48 Squamous 95 Non-Squamous 95 Non-Squamous Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 mg IV q3w Doc q3w atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w OS12.6 9.7 NR 11.1 15.1 7.4 15.1 9.2 9.7 9.7 10.1 8.6 14.8 10.9 POPLARPOPLAR 9032IINSCLC2 nd / 3 rd 144 imRECIST 144 RECIST 57 Atezo after PD 30 Other after PD Atezo 1200 mg IV q3w Atezo 1200 mg IV q3w Atezo 1200 q3w —> PD —> Atezo dose ND Atezo 1200 q3w —> PD —> Other Tx OS17% 15% 14% 4.2 2.7 11.1 8.3 IMvigor210IImUC ≧ 2 nd 100 IC2/3 imRECIST 207 IC1/2/3 imRECIST 310 IC0/1/2/3 imRECIST 100 IC2/3 RECIST 207 IC1/2/3 RECIST 310 IC0/1/2/3 RECIST Plat CTx —> PD —> R —> Atezo 1200 q3w 29% 23% 19% 26% 18% 15% 11.9 9. 0 7.9 50 (1- Yr) 40 (1- Yr) 37 (1- Yr) Abstract 35021bCRC ≧ 1 st 23 (22 KRASmu)Cobi + Atezo 800 q2wMTD (NR)17% Abstract 10091bmTNBC1 st 2 nd ≧ 3 rd ≧ 1 st (All) 9 8 7 24 Atezo 800 q2w + Pac Safety & tolerability (NR) 67%, 89% 35%, 75% 29%, 43% 42%, 71% (Conf., TBC) Treatments: Atezo 800 = Atezolizumab 800 mg IV; Atezo 1200 = Atezolizumab 1200 mg IV; Cobi = cobimetinib 20 - 60 mg daily 3wk on, 1 wk off; Doc = docetaxel 75 mg/m 2 ; IV; Pac = Nab-paclitaxel 125 mg/m 2 on d1,8,15 of 28 day cycles;Tx = Treatment. Abbreviations: 1 o EP = Primary Endpoint; BRAFmu = BRAF mutation; C2 = Cohort 2; Conf. = Confirmed; CRC = Colorectal Cancer; IC3/2/1/0 = high/medium/low/very low PDL1 expression on tumor-infiltrating immune cells; mOS = median Overall Survival; Mo = Months; mPFS = median Progression Free Survival; mTNBC = metastatic Triple Negative Breast Cancer; mUC = metastatic urothelial cancer; NR = Not Reported; NSCLC = non-small cell lung cancer; ORR = Overall Response Rate; OS; Overall Survival; PFS: Progression Free Survival; Ph = Phase; qXwk = every X weeks; R = Registration; TBC = To be confirmed; TC3/2/1/0 = high/medium/low/very low PD-L1 expression on tumor cells; Wk = Weeks; Yr = Year.

Download ppt "© MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after."

Similar presentations

James R. Rigas Comprehensive Thoracic Oncology Program

James R. Rigas Comprehensive Thoracic Oncology Program
Metastatic Gastric Cancer

Metastatic Gastric Cancer
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab:

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab:
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
First-Line TKI Use in EGFR Mutation-Positive NSCLC

First-Line TKI Use in EGFR Mutation-Positive NSCLC
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.

Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.
O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.

O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
Adam Heathfield, PhD Senior Director, Worldwide Policy, Pfizer Inc. September 25, 2013 Personalised Medicine – an industry perspective.

Adam Heathfield, PhD Senior Director, Worldwide Policy, Pfizer Inc. September 25, 2013 Personalised Medicine – an industry perspective.
Www.OncologyEducation.ca Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Www.OncologyEducation.ca A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.

A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.
Www.OncologyEducation.ca Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
May 29 - June 2, 2015 Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer CCO Independent Conference.

May 29 - June 2, 2015 Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer CCO Independent Conference.
ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR

ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR

Similar presentations

Ads by Google